Evid Invest
Holders — by stockHoldings — by fund

BlackBarn Capital Partners LP

Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0002010204

$1.19B

disclosed book value

21

positions

50.4%

largest position share

Positions, as of 2026-06-30

top 24 of 21 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held

#IssuerSharesValue% of book
1SPYSPDR S&P 500 ETF TRPUT800,000$597.4M50.4%
2ROIVANT SCIENCES LTD2.0M$70.8M6%
3OSCROSCAR HEALTH INCPUT1.8M$49.9M4.2%
4UNHUNITEDHEALTH GROUP INCCALL100,000$41.6M3.5%
5PRVAPRIVIA HEALTH GROUP INC1.6M$40.8M3.4%
6RMDRESMED INCPUT200,000$39.0M3.3%
7DHCDIVERSIFIED HEALTHCARE TR4.1M$37.9M3.2%
8VGVENTURE GLOBAL INCCALL3.0M$33.4M2.8%
9NEENEXTERA ENERGY INC335,000$29.4M2.5%
10NIQ GLOBAL INTELLIGENCE PLC2.9M$27.2M2.3%
11UNHUNITEDHEALTH GROUP INC65,000$27.0M2.3%
12NXP SEMICONDUCTORS N V90,000$25.3M2.1%
13VKTXVIKING THERAPEUTICS INC600,000$23.4M2%
14MHMCGRAW HILL INC2.5M$23.2M2%
15AMRXAMNEAL PHARMACEUTICALS INC1.3M$22.5M1.9%
16VGVENTURE GLOBAL INC1.8M$19.5M1.6%
17AZULAZUL S A1.7M$15.1M1.3%
18OXYOCCIDENTAL PETE CORP250,000$12.1M1%
19WRBYWARBY PARKER INCPUT400,000$12.1M1%
20ABUSARBUTUS BIOPHARMA CORP2.5M$12.0M1%
21VKTXVIKING THERAPEUTICS INCCALL250,000$9.8M0.8%
22CRCCALIFORNIA RES CORP175,000$9.3M0.8%
23CCOICOGENT COMMUNICATIONS HLDGS250,000$3.5M0.3%
24SEATVIVID SEATS INC500,000$3.3M0.3%

Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.

EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.